Dual-action tirzepatide delivers strong weight loss results by acting on both GIP and GLP-1 pathways. Offered with medical oversight and follow-up.
Tirzepatide is a GIP + GLP-1 receptor agonist shown in trials to produce substantial weight loss. It is generally reserved for patients who need a stronger metabolic effect and is prescribed following clinical assessment.
Mounjaro is intended for adults with obesity or those who require significant metabolic intervention. A doctor will evaluate risks, history, and suitability.
Tirzepatide is safe when prescribed and monitored by a doctor. Side effects and suitability are assessed before prescribing.